Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.07Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 0.97%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted solid revenue growth and successful product launches, particularly in the European market. However, challenges persist with operating losses, uncertainties in the Chinese market, and temporary impacts on recurring revenue margins. Overall, the sentiment is neutral, balancing positive developments with existing challenges.Company Guidance
During the Stereotaxis First Quarter 2025 Earnings Call, the company reported a 9% year-over-year growth in revenue, totaling $7.5 million, with system revenue at $2 million and recurring revenue at $5.5 million. The Map-iT catheter sales exceeded $1 million, growing 30% sequentially in the U.S. The European launch of the MAGiC catheter is expected to generate approximately $1 million per quarter by year-end, while the GenesisX soft launch has begun, with the first order received in Q1. Gross margins stood at 54%, with recurring revenue margins impacted by acquisition-related accounting. Operating expenses were $10 million, including $3.2 million in non-cash charges. The company reiterated its guidance for double-digit revenue growth for the full year 2025, with an expected recurring revenue of $7 million in Q4. The anticipated U.S. regulatory approval for MAGiC is in the second half of the year, and GenesisX approval is expected in the summer.Revenue Growth
The company reported a 9% year-over-year revenue growth for the first quarter, with total revenue reaching $7.5 million, up from $6.9 million in the prior year.
Map-iT Portfolio Success
The Map-iT family of EP catheters achieved sales over $1 million in the first quarter, with U.S. sales growing 30% sequentially from the fourth quarter.
MAGiC Catheter European Approval
The MAGiC ablation catheter received European approval, with initial adoption at approximately 20% of hospital customers.
GenesisX Launch
The company announced its first GenesisX purchase order and showcased the system at major electrophysiology conferences, receiving positive feedback.
Regulatory Progress
Significant progress on multiple fronts, including ongoing regulatory reviews of key technologies such as MAGiC in the U.S., GenesisX in the U.S., and MAGiC Sweep.
Revenue Guidance
The company reiterated its revenue guidance, expecting double-digit growth for the full year 2025 and recurring revenue reaching $7 million in the fourth quarter.
STXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.07 | $2.11 | +1.93% |
Mar 03, 2025 | $2.06 | $1.94 | -5.83% |
Nov 11, 2024 | $1.85 | $2.26 | +22.16% |
Aug 12, 2024 | $1.80 | $2.01 | +11.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Stereotaxis (STXS) report earnings?
Stereotaxis (STXS) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Stereotaxis (STXS) earnings time?
Stereotaxis (STXS) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STXS EPS forecast?
STXS EPS forecast for the fiscal quarter 2025 (Q2) is -0.07.